Status:
RECRUITING
Autologous Non-cultured Epidermal Cell Suspension Transplantation in the Treatment of Vitiligo
Lead Sponsor:
Peking University People's Hospital
Conditions:
Vitiligo
Eligibility:
All Genders
8-65 years
Phase:
NA
Brief Summary
To observe the long-term efficacy and safety of autologous non cultured epidermal cell suspension transplantation in the treatment of vitiligo, analyze the correlation between cell density, type, and ...
Detailed Description
1\. Patient recruitment Inclusion criteria： 1. Patients diagnosed as vitiligo, according to the "Vitiligo Diagnosis and Treatment Consensus (2021 edition) 2. Segmental and unclassified vitiligo stabl...
Eligibility Criteria
Inclusion
- Patients diagnosed as vitiligo, according to the "Vitiligo Diagnosis and Treatment Consensus (2021 edition)
- Segmental and unclassified vitiligo stable for 6 months, Non-segmental vitiligo stable for 1 year and resistant to medication and phototherapy
- BSA≥5%
- Sign the informed consent and be willing to undergo surgical treatment
- 8-65 years old, both genders
Exclusion
- Severe visceral or infectious disease not suitable for surgical treatment
- Tendency toward keloid formation
- Coagulation defects
- Unable to complete follow-up on time
Key Trial Info
Start Date :
April 25 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT07187882
Start Date
April 25 2024
End Date
December 31 2025
Last Update
September 23 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University People's Hospital
Beijing, Beijing Municipality, China, 100044